2012

December 2012

• "Chair introduction"  
• Dr. Christopher Bravery, PhD
• Chair, speaker, panel discussion, workshop.
• Informa LIfe Sciences' 3rd annual cell therapy manufacturing
• Brussels, Belgium

 

September 2012

•  "Regulatory implications of Allogeneic cell banking strategy" 
• Dr. Christopher Bravery, PhD
• Speaker
• IBC's 2nd annual cell therapy Bioprocessing
• Arlington, VA USA

• "Reference materials for cell-based medicinal products: An industry perspective"
• Dr. Christopher Bravery, PhD
• Speaker
• 11^th international symposium on pharmaceutical reference standards 
• EDQM, Strasbourg, France.

 

July 2012

• "The importance of characterisation in immunotherapy product development" 
• Dr. Christopher Bravery, PhD
• Speaker
• Innovative cell and tissue biotherapies
• Marseille, France

 

June 2012

• "Oral Abstract: Regulatory Implications of Allogeneic Cell Banking Strategy "  
• Dr. Christopher Bravery, PhD
• ISCT 2012 Annual Meeting
  
• Seattle, WA USA
  

• "Are biosimilar cell therapy products possible?"
• Dr. Christopher Bravery, PhD
• Bioprocessing and Stem Cells Europe 2012: Biosciences Biotherapeutics.
• Speaker
• London, UK

May 2012 

• "Chair introduction"
• Christopher Bravery, PhD
• World stem cells and regenerative medicine congress Europe 2012
• Chair
• London, UK  

 

February 2012

• "WP1: Regulation" 
• Christopher A, Bravery, PhD. 
• VALUE. Regenerative Medicine: Navigating the uncertainties
• Speaker
• London, UK